<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126051">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461499</url>
  </required_header>
  <id_info>
    <org_study_id>SMART-2</org_study_id>
    <nct_id>NCT01461499</nct_id>
  </id_info>
  <brief_title>Shiga Microalbuminuria Reduction Trial-2</brief_title>
  <official_title>Clinical Investigation on the Effects of Reducing Microalbuminuria in Hypertensive Patients With Type 2 Diabetes - SMART2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shiga University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shiga University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effects of a direct renin inhibitor (DRI),
      aliskiren, on the urinary albumin excretion in hypertensive patients with type 2 diabetes
      under strict blood pressure control with angiotensin receptor blocker (ARB).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in albuminuria</measure>
    <time_frame>baseline and 24 weeks</time_frame>
    <description>Change in the urinary albumin to creatinine ratio (UACR) from the baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the urinary angiotensinogen level</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the plasma renin activity</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the serum insulin level</measure>
    <time_frame>baseline and 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">237</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Direct renin inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Angiotensin receptor blockers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>The patient will start taking one a daily 150 mg/day of aliskiren. In case blood pressure doesn't reach the target (SBP/DBP &lt; 130/80 mmHg), higher dose of aliskiren will be given.In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.</description>
    <arm_group_label>Direct renin inhibitor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>any angiotensin receptor blockers</intervention_name>
    <description>The patient will start taking one a standard dose of an ARB in Japan. In case blood pressure doesn't reach the target (SBP/DBP &lt; 130/80 mmHg), higher dose of the ARB will be given. In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (DRI, another ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.</description>
    <arm_group_label>Angiotensin receptor blockers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Segment: outpatients

          -  Hypertension: taking an anti-hypertensive treatment or indicating mean sitting
             SBP/DBP more than130/80 mmHg

          -  Type 2 diabetes: diagnosed by ADA criteria or under an anti-diabetic drug treatment

          -  Microalbuminuria: 10 &lt; and &lt; 300 mg/gCr

          -  Informed consent: patients who understand well about this study based on own
             voluntary will and can give a written consent

        Exclusion Criteria:

          -  Sever hypertension (over 180/110 mmHg), malignant hypertension and secondary
             hypertension

          -  Type 1 diabetes

          -  Patients whose investigator regards as difficult to comply with study protocol in
             reference to the package insert of aliskiren

          -  Patients who have history of operation in gastrointestinal tract surgery, and
             anamnestic or concurrent gastrointestinal disorders, which may interfere with drug
             absorption

          -  Serum potassium &gt; 5.6 mEq/L (hyperkalemia)

          -  Urinary microalbmiurin &lt; 10 or &gt; 300 mg/gCr

          -  Patients who participated in another clinical study within three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroshi Maegawa, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Shiga University of Medical Science</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shiga University of Medical Science</name>
      <address>
        <city>Otsu</city>
        <state>Shiga</state>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <lastchanged_date>October 21, 2014</lastchanged_date>
  <firstreceived_date>October 19, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shiga University</investigator_affiliation>
    <investigator_full_name>Hiroshi Maegawa</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Albuminuria</keyword>
  <keyword>Direct renin inhibitor</keyword>
  <keyword>Angiotensin receptor blocker</keyword>
  <keyword>Type 2 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
